Wall Street analyst estimates for Lixte Biotechnology Holdings, Inc. (LIXT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Lixte Biotechnology Holdings, Inc. is a drug discovery company focused on developing new treatments. It employs biomarker technology to identify crucial enzyme targets associated with serious, widespread diseases, then designs innovative compounds to act upon these targets.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-05-14 | $-0.18 | ||
| 2026-03-31 | $-0.33 | ||
| 2025-11-12 | $-0.33 | ||
| 2025-08-07 | $-0.29 | ||
| 2025-05-12 | $-0.29 | ||
| 2025-03-24 | $-0.27 | ||
| 2024-11-12 | $-0.44 | ||
| 2024-08-08 | $-0.45 |
Valuation Ratios
| Price / Book | 4.06 |
| EV / EBITDA | -30.96 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $1.3M | $467258 | $40703 | $820906 | $1.2M | $1.7M | $1.3M | $898100 | $726232 | $254919 |
| Selling, General & Admin | $833782 | $1.3M | $2.1M | $1.7M | $2.0M | $5.0M | $5.0M | $4.2M | $2.8M | $4.9M |
| Operating Expenses | $2.1M | $1.8M | $2.1M | $2.5M | $3.3M | $6.7M | $6.3M | $5.1M | $3.6M | $5.1M |
| Operating Income | -$2.1M | -$1.8M | -$2.1M | -$2.5M | -$3.3M | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$5.1M |
| EBITDA | $183 | $1375 | $4923 | -$2.4M | 0 | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$6.0M |
| Interest Expense | $183 | $1375 | $4923 | 0 | $3674 | $7414 | $8875 | $16233 | $16821 | $9158 |
| Pre-tax Income | -$2.1M | -$1.8M | -$2.1M | -$2.4M | -$3.3M | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$6.0M |
| Income Tax | -$2135 | -$1810 | -$9846 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$2.1M | -$1.8M | -$2.1M | -$2.4M | -$3.3M | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$6.0M |
| EPS | $-2.68 | $-1.94 | $-2.18 | $-2.20 | $-2.89 | $-5.00 | $-4.00 | $-2.66 | $-1.59 | $-1.26 |
| EPS (Diluted) | $-2.68 | $-1.94 | $-2.18 | $-2.20 | $-2.89 | $-5.00 | $-4.00 | $-2.66 | $-1.59 | $-1.26 |
| Shares Outstanding (Diluted) | $797930 | $930290 | $979935 | $1.1M | $1.1M | $1.3M | $1.6M | $1.9M | $2.2M | $48.4M |
Price
| Price | $7.21 |
| Market Cap | $89M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALLR · BCTX · CASI · CING · CLSD · ENTO · HOTH
Explore sector: Healthcare · Biotechnology
More sections of LIXT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks